- Source type
- Article
- Access type
- Publisher
- Publisher
- Live Science
- Added
- 2026-07-09
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 54/100
- Weak Support
- Clinical outcomes
- 54/100
- Weak Support
- Mechanism
- 54/100
- Weak Support
- Safety
- 54/100
- Weak Support
- Consumer context
- 67/100
- Context Source
- Trial discovery
- 54/100
- Weak Support
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
FDA Approved the First Gene Therapy for Inherited Deafness
Roles: Background
Show section-level references
- FDA approved Otarmeni, an AAV gene therapy for severe-to-profound hearing loss caused by biallelic OTOF variants in patients with preserved outer hair cell function and no prior cochlear implant in the treated ear. Trial reports show meaningful hearing improvement in many treated children, but this is not a cure for all deafness and does not restore normal hearing for every patient.Consumer science context for the inherited-deafness approval story.
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: first-in-human EPI-321 study in FSHD
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
UCSF Clinical Trials: NGN-401 Rett syndrome study
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- UCSF Clinical Trials
- Access
- Publisher
- Usage
- 1 connection
FDA: Casgevy expanded to young children with sickle cell disease
Primary regulatory source for the July 2026 Casgevy age-expansion brief.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
CIRM: clinical and preclinical development awards
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- CIRM
- Access
- Official
- Usage
- 1 connection
CIRM: more than $60M for clinical and preclinical development awards
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- CIRM
- Access
- Official
- Usage
- 1 connection
EMA: Vyjuvek EPAR
European regulatory context for the therapy; not proof of Australian reimbursement or access.
- Trust score
- 94
- Publisher
- European Medicines Agency
- Access
- Publisher
- Usage
- 1 connection